Takeuchi, Shoko
Doi, Manami
Ikari, Naoki
Yamamoto, Masakazu
Furukawa, Toru http://orcid.org/0000-0002-1083-2324
Article History
Received: 23 January 2018
Accepted: 14 May 2018
First Online: 25 May 2018
Competing Interests
: Regarding this study, T.F. was funded by AstraZeneca. Olaparib, a commercial product of AstraZeneca, was discussed in this study. The funder did not play any role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of this manuscript. T.F. does not have any other potential conflicts of financial as well as non-financial interest. S.T., M.D., N.I. and M.Y. declare no potential conflict of interest.